ESSA Pharma And 2 Other US Penny Stocks To Watch

As the U.S. stock market reaches record highs amid an election-fueled rally, investors are increasingly exploring diverse opportunities to capitalize on this momentum. Penny stocks, often seen as a relic of past trading days, still hold significant potential for growth and value discovery in today's market landscape. These smaller or newer companies can offer a mix of affordability and upside potential when backed by strong financials, presenting an underappreciated avenue for investors seeking hidden gems in the stock market.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Financial Health Rating
BAB (OTCPK:BABB)	$0.7656	$5.56M	★★★★★★
RLX Technology (NYSE:RLX)	$1.63	$2.07B	★★★★★★
QuantaSing Group (NasdaqGM:QSG)	$3.08	$170.72M	★★★★★★
AsiaFIN Holdings (OTCPK:ASFH)	$0.97	$79.11M	★★★★★★
Flexible Solutions International (NYSEAM:FSI)	$4.10	$51.05M	★★★★★★
PHX Minerals (NYSE:PHX)	$3.44	$128.99M	★★★★★☆
So-Young International (NasdaqGM:SY)	$1.25	$88.26M	★★★★☆☆
Permianville Royalty Trust (NYSE:PVL)	$1.55	$51.15M	★★★★★★
Puma Biotechnology (NasdaqGS:PBYI)	$2.88	$141.25M	★★★★★★
CBAK Energy Technology (NasdaqCM:CBAT)	$1.07	$96.23M	★★★★★☆

Click here to see the full list of 740 stocks from our US Penny Stocks screener.

Let's explore several standout options from the results in the screener.

ESSA Pharma (NasdaqCM:EPIX)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: ESSA Pharma Inc. is a clinical-stage pharmaceutical company dedicated to developing small molecule drugs for prostate cancer treatment, with a market cap of $79.86 million.

Operations: ESSA Pharma Inc. has not reported any revenue segments as it is currently focused on the clinical development of small molecule drugs for prostate cancer treatment.

Market Cap: $79.86M

ESSA Pharma Inc., a pre-revenue company with a market cap of US$79.86 million, recently terminated its Phase 2 clinical trial for masofaniten due to lack of efficacy compared to standard treatment. Despite this setback, the company maintains a strong cash position with short-term assets of US$132.1 million far exceeding liabilities and no debt on its books, providing it with over three years of cash runway at current burn rates. While the stock is highly volatile and unprofitable, analysts forecast significant earnings growth ahead, supported by seasoned management and board experience.

• Get an in-depth perspective on ESSA Pharma's performance by reading our balance sheet health report here.
• Review our growth performance report to gain insights into ESSA Pharma's future.

Identiv (NasdaqCM:INVE)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Identiv, Inc. is a security technology company offering secure identification and physical security solutions globally, with a market cap of $92.73 million.

Operations: Identiv, Inc. does not report specific revenue segments.

Market Cap: $92.73M

Identiv, Inc., with a market cap of US$92.73 million, remains unprofitable and has seen losses increase over the past five years. Despite this, it maintains a strong financial position with no debt and short-term assets of US$166 million far exceeding its liabilities. Recent earnings reports show declining sales but a surprising net income swing due to extraordinary items. The company is actively seeking acquisitions as part of its strategic growth plan while also implementing a share repurchase program worth up to US$10 million. Identiv's focus on sustainability through NFC technology could drive future opportunities in digital product passports.

• Click here and access our complete financial health analysis report to understand the dynamics of Identiv.
• Gain insights into Identiv's future direction by reviewing our growth report.

Scienjoy Holding (NasdaqCM:SJ)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Scienjoy Holding Corporation operates mobile live streaming platforms in the People’s Republic of China, with a market cap of $41.80 million.

Operations: The company generates revenue from its Internet Telephone segment, amounting to CN¥1.49 billion.

Market Cap: $41.8M

Scienjoy Holding Corporation, with a market cap of $41.80 million, operates in the volatile penny stock space. The company has no debt and boasts short-term assets of CN¥530.7 million surpassing its liabilities, indicating a stable financial footing despite being unprofitable with increasing losses over five years at 27.7% annually. Recent earnings show revenue growth to CN¥374.84 million for Q2 2024 but declining net income compared to the previous year. Scienjoy regained Nasdaq compliance by maintaining a share price above $1 for ten days, reflecting some stability amidst high volatility and ongoing strategic presentations at industry events like LD Micro Main Event XVII.

• Click to explore a detailed breakdown of our findings in Scienjoy Holding's financial health report.
• Learn about Scienjoy Holding's historical performance here.

Turning Ideas Into Actions

• Navigate through the entire inventory of 740 US Penny Stocks here.
• Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.
• Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor.

Seeking Other Investments?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com